Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 24;17(8):979.
doi: 10.3390/ph17080979.

New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology

Anna Frostegård  1   2 , Anders Haegerstrand  1
Affiliations
Review

New Therapeutic Strategies in Retinal Vascular Diseases: A Lipid Target, Phosphatidylserine, and Annexin A5-A Future Theranostic Pairing in Ophthalmology

Anna Frostegård et al. Pharmaceuticals (Basel). .

Abstract

Despite progress in the management of patients with retinal vascular and degenerative diseases, there is still an unmet clinical need for safe and effective therapeutic options with novel mechanisms of action. Recent mechanistic insights into the pathogenesis of retinal diseases with a prominent vascular component, such as retinal vein occlusion (RVO), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD), may open up new treatment paradigms that reach beyond the inhibition of vascular endothelial growth factor (VEGF). Phosphatidylserine (PS) is a novel lipid target that is linked to the pathophysiology of several human diseases, including retinal diseases. PS acts upstream of VEGF and complement signaling pathways. Annexin A5 is a protein that targets PS and inhibits PS signaling. This review explores the current understanding of the potential roles of PS as a target and Annexin A5 as a therapeutic. The clinical development status of Annexin A5 as a therapeutic and the potential utility of PS-Annexin A5 as a theranostic pairing in retinal vascular conditions in particular is described.

Keywords: Annexin A5; anti-VEGF; phosphatidylserine; retinal vein occlusion.

PubMed Disclaimer

Conflict of interest statement

Authors are employees of Annexin Pharmaceuticals and own stocks in the company.

References

    1. Blindness G.B.D., Vision Impairment C., Vision Loss Expert Group of the Global Burden of Disease Study Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The Right to Sight: An analysis for the Global Burden of Disease Study. Lancet Glob. Health. 2021;9:e144–e160. doi: 10.1016/S2214-109X(20)30489-7. - DOI - PMC - PubMed
    1. Campochiaro P.A. Retinal and Choroidal Vascular Diseases: Past, Present, and Future: The 2021 Proctor Lecture. Investig. Ophthalmol. Vis. Sci. 2021;62:26. doi: 10.1167/iovs.62.14.26. - DOI - PMC - PubMed
    1. Tah V., Orlans H.O., Hyer J., Casswell E., Din N., Sri Shanmuganathan V., Ramskold L., Pasu S. Anti-VEGF Therapy and the Retina: An Update. J. Ophthalmol. 2015;2015:627674. doi: 10.1155/2015/627674. - DOI - PMC - PubMed
    1. Bhisitkul R.B., Campochiaro P.A., Blotner S., Quezada-Ruiz C., Liu M., Haskova Z. Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: Relationship between injection need and vision with as-needed ranibizumab. Br. J. Ophthalmol. 2024 doi: 10.1136/bjo-2022-323120. - DOI - PMC - PubMed
    1. Patel S.B., Heier J.S., Chaudhary V., Wykoff C.C. Treatment of geographic atrophy: An update on data related to pegcetacoplan. Curr. Opin. Ophthalmol. 2024;35:64–72. doi: 10.1097/ICU.0000000000000845. - DOI - PubMed

LinkOut - more resources